impact factor
logo
 

Full Papers

 

Efficacy of intravenous neridronate in transient osteoporosis of the hip


1, 2, 3, 4, 5, 6, 7, 8, 9, 10

 

  1. Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy. rt.dalessandro@gmail.com
  2. Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
  3. Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
  4. Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
  5. Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
  6. Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
  7. Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
  8. Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
  9. Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
  10. Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.

CER15035
Full Papers

purchase article

PMID: 35084313 [PubMed]

Received: 26/07/2021
Accepted : 18/10/2021
In Press: 03/01/2022

Abstract

OBJECTIVES:
To evaluate the efficacy and safety of intravenous (iv) neridronate in patients affected by transient osteoporosis of the hip (TOH).
METHODS:
We retrospectively evaluated the clinical records of patients affected by TOH treated with iv neridronate in our department. We treated patients with a value of visual analogue scale (VAS)-pain ≥ 80/100 mm at diagnosis, limited range of movement and magnetic resonance images (MRI) findings suggestive of TOH. The regimen used was: one iv infusion at day 0, 3, 6, 9 (100 mg for each infusion: total of 400 mg). This protocol was repeated in refractory cases. Recovery was defined as VAS-pain level ≤20/100. Concomitant use of analgesics was allowed. Paired Student t-test was used to assess VAS-pain change.
RESULTS:
Five patients were male, 3 were female. Mean age was 54.5±2.12 years old. Mean body mass index was 26.57±2.22. Mean time to diagnosis, since the onset of the symptoms, was 75±21.21 days. Mean number of neridronate infusions was 7.5±2.56. Mean time of recovery was 57±45.96 days. Mean VAS-pain at baseline was 84±2,24. Mean VAS-pain after treatment was significantly reduced (p<0.001) with a value of 12.12±6.46. None of the patients needed analgesics after treatment. No adverse event was reported. In 5 cases, post-treatment MRI showed complete bone marrow oedema resolution.
CONCLUSIONS:
Intravenous neridronate is effective and safe in the treatment of TOH and its use may lead to a faster resolution of the disease.

DOI: https://doi.org/10.55563/clinexprheumatol/vzknda

Rheumatology Article